Latest - Page 2 of 4 - Rivervest - News & Press / Case Studies / Articles

News & Press

RiverVest Venture Partners Closes on Oversubscribed $184.4 Million Life Science Fund

News & Press

RiverVest Venture Partners’ Portfolio Company Securus Sold to Boston Scientific Represents 9th Exit from RiverVest Venture Fund II

News & Press

RiverVest Venture Partners Expands Scientific Advisory Board

News & Press

St. Louis Venture Fund Makes $15 Million Bet on its Hometown

News & Press

RiverVest Venture Partners Closes on $15 Million Biopharma Pre-Seed Fund

News & Press

RiverVest Venture Partners co-leads $86 million Series A financing for St. Louis-founded startup Tioma

Mirum Pharmaceuticals Announces First Patient Enrolled in Phase 2b VISAS Clinical Study Evaluating Volixibat in Adult Patients With Primary Sclerosing Cholangitis – 01/14/2021
Mirum Pharmaceuticals Provides Corporate Update – 01/12/2021
Mirum Pharmaceuticals Announces Pricing of Public Offering of Common Stock – 12/14/2020
Mirum Pharmaceuticals and Oberland Capital Announce Up to $210 Million Funding Arrangement – 12/09/2020
Reneo Pharmaceuticals Raises $95 Million in Series B Financing, Co-led by Novo Ventures and Abingworth – 12/09/2020
Arch Oncology Announces First Patient Dosed in Phase 1/2 Clinical Trial of Anti-CD47 Antibody AO-176 in Multiple Myeloma — 12/07/2020
Mirum Pharmaceuticals Announces European Medicines Agency Validation of the Marketing Authorization Application for Maralixibat in Patients with PFIC2 – 11/30/2020
Xilio Therapeutics Presents Promising Preclinical Tumor-Selective Efficacy and Safety Data for XTX201 (IL-2) and XTX101 (anti-CTLA-4) at SITC – 11/12/2020
Allakos Announces Presentation from its Eosinophilic Gastrointestinal Diseases Program at the American College of Gastroenterology (ACG) 2020 Annual Scientific Meeting – 11/2/2020
Mirum Pharmaceuticals Announces New Data Being Presented in Late-Breaker Oral and Poster Presentations at the Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) – 11/2/2020
Scout Bio Advances Novel Gene Therapy for the Treatment of Feline Diabetes – 10/28/2020
Allakos Announces Results from a Phase 1 Study of Subcutaneously Administered Lirentelimab (AK002) – 10/26/2020
Results from Allakos’s Prospective Prevalence Study Indicate that Eosinophilic Gastritis and Eosinophilic Duodenitis May be Significantly Underdiagnosed – 10/26/2020
Allakos Announces Publication of Results from the Phase 2 Study of Lirentelimab (AK002) in Patients with Eosinophilic Gastritis and/or Eosinophilic Duodenitis (ENIGMA) in the New England Journal of Medicine – 10/21/2020
VentureMed’s FLEX Vessel Prep™ System Receives New Indication to Address In-Stent Restenosis – 10/21/2020
Spruce Biosciences Announces Pricing of Upsized Initial Public Offering – 10/8/2020
Mirum Pharmaceuticals Presents Maralixibat Five-Year Transplant-Free Survival Data for Patients with PFIC2 at Digital International Liver Congress 2020 – 8/29/2020
Allakos Reports Second Quarter 2020 Financial Results and Provides Business Update – 8/10/2020
Mirum Pharmaceuticals Announces Second Quarter 2020 Financial Results and Provides Program Updates – 8/6/2020
Amplyx Announces Positive Top-Line Data in Phase 2 Clinical Trial of Novel Antifungal Fosmanogepix – 7/20/2020
Reneo Pharmaceuticals Completes Clinical Study in Primary Mitochondrial Myopathies and Receives FDA Orphan Drug Designation for REN001 – 6/23/2020
Mirum’s Maralixibat Demonstrates Transplant-Free Survival for Pediatric Patients with Progressive Familial Intrahepatic Cholestasis – 6/2/2020
Avalyn Pharma Secures $35.5 Million Series B Financing, Broadens Development Portfolio – 4/27/2020
Arch Oncology Appoints Biotechnology Industry Veteran Julie Hambleton, M.D. to Board of Directors. – 4/21/2020
Horizon Therapeutics plc Acquires Curzion Pharmaceuticals, Inc. and Its LPAR1 Antagonist Product Candidate to Expand Development-Stage Pipeline – 4/2/2020
Mirum Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate Update – 3/12/2020
Akrevia Therapeutics Rebrands as Xilio Therapeutics and Announces $100.5 Million Series B Financing – 3/2/2020
Spruce Biosciences Raises $88 Million in Series B Financing, co-led by Omega Funds and Abingworth – 2/19/2020
InterVene, Inc. Wins TCT 2019 Shark Tank Innovation Competition – 9/29/2019
Reneo Pharmaceuticals Initiates Clinical Trial in McArdle Disease – 2/18/2020
Mirum Pharmaceuticals Announces Pricing of Public Offering – 1/8/2020
Mirum Pharmaceuticals Completes Successful Pre-NDA Meeting with FDA for Maralixibat – 12/16/2019
Allakos Reports Third Quarter 2019 Financial Results – 11/12/2019
Mirum Pharmaceuticals Announces Breakthrough Therapy Designation for Maralixibat for the Treatment of Pruritus Associated with Alagille Syndrome – 10/28/2019
Spruce Biosciences Announces Positive Results from 12-week, Phase 2a Study of Tildacerfont in Adults with Congenital Adrenal Hyperplasia – 09/19/2019

This site uses cookies. By continuing to browse the site, you are agreeing to our use of cookies.

Learn More

RiverVest Venture Partners Closes on Oversubscribed $184.4 Million Life Science Fund

RiverVest Venture Partners’ Portfolio Company Securus Sold to Boston Scientific Represents 9th Exit from RiverVest Venture Fund II

RiverVest Venture Partners Expands Scientific Advisory Board

St. Louis Venture Fund Makes $15 Million Bet on its Hometown

RiverVest Venture Partners Closes on $15 Million Biopharma Pre-Seed Fund

RiverVest Venture Partners co-leads $86 million Series A financing for St. Louis-founded startup Tioma

Get Directions

Get Directions

Get Directions